awmsg logo



bortezomib (Velcade®)


Reference No. 66

Publication date:
01/06/2010


Appraisal information

bortezomib (Velcade®) 3.5 mg powder for solution for injection


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 17/03/2010
AWMSG meeting date: 28/04/2010
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0510
Ministerial ratification: 28/05/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA228) NICE GUIDANCE ISSUED JULY 2011 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Bortezomib (Velcade®) is recommended as an option for use within NHS Wales in combination with melphalan and prednisone* for the treatment of patients with previously untreated multiple myeloma (MM) who are not eligible for high-dose chemotherapy (HDT) with bone marrow transplant (BMT). AWMSG is of the opinion that bortezomib (Velcade®) is not suitable for shared care within NHS Wales. * The licence and trials specify the use of prednisone. This is not available in the UK, where a direct substitution of prednisolone for prednisone is made as they are considered dose-equivalent.